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Background
Non-inferiority (NI) trials test a hypothesis that a new
treatment is inferior to standard treatment only to a
negligible degree. Bio-creep basically refers to the cycli-
cal phenomenon where a slightly inferior treatment
becomes the active control for the next generation of NI
trials which over time leads to degradation of the effi-
cacy of the investigational treatment [1,2]. We studied
the effect estimates from an unselected set of all the
registered non-inferiority trials conducted within a
seven-year period. The aim was to determine the pre
and post trial distribution of the true effect in NI trials
from this data using meta-analytic methods.
Methods
We did a search for all NI trials registered in the
National Library of Medicine (NLM)’s Clinical trials reg-
ister [http://www.ClinicalTrials.gov] [3] which was car-
ried out between January 2000 and December 2007.
Trials studying non-inferiority of efficacy as the primary
objective were only included. We did a search for infor-
mation regarding the primary results from these trials in
the following steps: the NLM website [3], The Pharma-
ceutical Research and Manufacturers of America
(PhRMA) [4], the International Federation of Pharma-
ceutical Manufacturers and Associations (IFPMA) web-
site [5] and Pubmed. Web-based search engines and
personal communication were also used. Using the
retrieved study results, a descriptive and exploratory
analysis of the study characteristics and a meta-analysis
of the effect estimates were performed using STATA 11
[6].
Results
Of the 113 registered NI trials, 83 met the inclusion and
exclusion criteria. The final results were available for 63
of the 74 completed studies with result estimates with
the help of NLM website-44, PhRMA-2, Pharmaceutical
websites-7, Pubmed-18 and others-3. The final results
were available for 63 of the 74 completed studies. The
source of the study results and effect estimates were 53
scientific journal articles, 13 clinical study reports, 4
press releases and 4 reported on the register records.
We intend to present the distribution of true effect of
NI trials derived based on the above estimates.
Conclusion
We found a very high likelihood of retrieving results
from registered clinical trials making it possible to cal-
culate the pre-study distribution of the true effect in
non-inferiority trials. The unanticipated finding of a
positive average effect estimate suggests that a decline in
standard treatment effect (biocreep) is not imminent, at
least on average. However, the intimidating risk of
approval of treatments with true negative effects reiter-
ates the need for a careful choice of the margin in NI
trials.
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